Further, inhibition of CARM1 activity using EZM2302 slows nonHodgkin DLBCL growth in both in vitro models and in vivo xenograft models and the level of sensitivity to EZM2302 is positively correlated with the CBP/EP300 mutation load (64). The gene discussed is EP300; the disease is diffuse large B-cell lymphoma.